Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Myocardial Suppression
Interventions
OTHER

Fast + High-fat low-carbohydrate diet

Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.

COMBINATION_PRODUCT

Fast + Empagliflozin

Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.

Trial Locations (1)

H1T1C8

Montreal Heart Institute, Montreal

All Listed Sponsors
lead

Matthieu Pelletier-Galarneau, MD MSc

OTHER

NCT06350903 - Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging | Biotech Hunter | Biotech Hunter